1. Draw 2 mL bacteriostatic water with a sterile syringe.
2. Inject slowly down the vial wall; avoid foaming.
3. Gently swirl until dissolved (do not shake).
4. Label and refrigerate at 2 to 8 °C, protected from light; use within 2 weeks. At 10 mg/mL, 1 unit = 0.01 mL = 100 mcg (0.1 mg) on a U-100 insulin syringe.

Prostamax (KEDP) belongs to the class of short bioregulatory peptides studied by Khavinson and colleagues. These tetrapeptides are proposed to modulate gene expression through epigenetic mechanisms, interacting with chromatin structure and histone proteins. In aged human lymphocytes, KEDP has been observed to cause pericentromeric chromatin decondensation, potentially reactivating suppressed genes. Preclinical rat models of prostatitis showed that IM administration of KEDP reduced inflammatory markers and helped prevent fibrotic changes in prostate tissue.

• In rat prostatitis models, IM KEDP administration reduced inflammation and supported tissue
  normalization over 15 to 60 days.
• Studies in benign prostatic hyperplasia models showed favorable effects on prostate weight and
  histological parameters.
• Short bioregulatory peptides of this class generally show favorable tolerability profiles in preclinical work.
• Potential for mild injection-site reactions (redness, tenderness) as with any IM administration; rotate sites
  to minimize.
• Human clinical trial data are not yet published; dosing is extrapolated from animal models.